Rhinitis, Allergic, Seasonal Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled First Time Into Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intranasal Dosing With GSK2245035, a TLR7 Agonist, in Healthy Volunteers and Allergic Rhinitics
GSK2245035 is a highly selective Toll-like Receptor 7(TLR7) agonist capable of preferentially inducing the production of interferon alpha (IFNα) versus tumor necrosis factor alpha (TNFα). The aim of this FTIH study is to collect tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) information to enable the identification of appropriate safe doses of intranasal (i.n) GSK2245035, associated with up-regulation of TLR7-mediated genes in the nasal milieu, for use in subsequent clinical drug development studies. There will be two parts to the study: Healthy Volunteers will be dosed in escalating single doses in Part 1, followed by Allergic Rhinitis (AR) subjects dosed similarly in Part 2.
This is a First Time in Human (FTIH) study to investigate the safety, tolerability,
pharmacokinetics (PK) and pharmacodynamics (PD) of single, escalating doses of intranasal
(i.n.) GSK2245035 in healthy male volunteers (HVT) and male subjects with allergic rhinitis
(AR). The safety and tolerability of single i.n. GSK2245035 dosing will be assessed and
established in HVT before the initiation of evaluation in AR.
GSK2245035 is a highly selective Toll-like Receptor 7 (TLR7) agonist capable of
preferentially inducing the production of IFNα rather than TNFα. Activation of TLR7 is known
to result in upregulation of co-stimulatory signals on antigen-presenting cells and in
generation of pro-inflammatory mediators that can shift bystander immune responses towards a
Helper T-cell Type 1/ Regulatory T cell (Th1/Treg) phenotype and therefore reduce the
magnitude of Helper T-cell Type 2 (Th2) reactivity. In this context, it is proposed that
i.n. GSK2245035 administration may alter the airways immune environment in a way that
results in long-lasting control of AR symptoms and potentially disease remission through
persistent modification of the underlying aberrant Th2 responsiveness to aeroallergens.
The aim of this study is to collect tolerability, PK and PD information to enable the
identification of appropriate safe doses of i.n. GSK2245035, associated with up-regulation
of TLR7-mediated genes in the nasal milieu, for use in subsequent clinical drug development
studies. The study will be divided in to two parts. Part 1, involving only healthy
volunteers, will consist of 8 cohorts receiving doses from 2 nanograms (2 ng) to 4000ng or a
placebo dose. Administration within each cohort will be staggered so that two subjects (one
receiving drug and one placebo) will be dosed and monitored for 24 hours before any
subsequent doses.
Screening for part 2 of the study will begin once data from cohort 4 in part 1 has been
found to be satisfactory. Part 2 will involve subjects with Allergic Rhinitis and be divided
into three cohorts receiving doses between 20ng and 4000ng or a placebo dose.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01337323 -
Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting
|
N/A | |
Completed |
NCT00851344 -
Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo
|
Phase 2 | |
Completed |
NCT00537355 -
An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber
|
Phase 2 | |
Completed |
NCT00501527 -
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
|
Phase 2 | |
Completed |
NCT00422149 -
Twin SUBLIVAC® Grasses Clinical Efficacy Study
|
Phase 3 | |
Completed |
NCT00542607 -
Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT00605852 -
Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
Completed |
NCT02256553 -
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
|
Phase 4 | |
Completed |
NCT01007721 -
Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season
|
Phase 2 | |
Completed |
NCT00932256 -
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients
|
Phase 1 | |
Completed |
NCT00901914 -
Study of rBet v1 Tablets
|
Phase 2 | |
Completed |
NCT00384475 -
A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)
|
Phase 3 | |
Completed |
NCT00839189 -
Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults
|
Phase 1 | |
Completed |
NCT00135629 -
Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever
|
Phase 3 | |
Completed |
NCT04687059 -
An Exploratory Study of PQ Grass 27600 SU
|
Phase 2/Phase 3 | |
Completed |
NCT00889460 -
Safety and Tolerability Study of rBet v1 SLIT Tablets
|
Phase 1 | |
Completed |
NCT00396149 -
Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1
|
Phase 1 | |
Completed |
NCT00659594 -
Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)
|
Phase 3 | |
Completed |
NCT00127647 -
An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)
|
Phase 3 |